Evaluation of Agents to Reduce Infarct Size

Erythropoietin and Myocardial Infarction

“…Therefore, evidence strongly suggests that erythropoiesis stimulating agents might also carry a cardiovascular risk in the short term 5 . Contrary to the authors’ opinions, short‐term clinical events appear in patients that received rHuEpo.…”

“…Th erefore, evidence strongly suggests that erythropoiesis stimulating agents might also carry a cardiovascular risk in the short term. 5 Contrary to the authors' opinions, short-term clinical events appear in patients that received rHuEpo. In this setting, more data are needed to support erythropoiesis stimulation, increasing hematocrit, and blood viscosity, in patients with high risk of cardiovascular events.…”

Surrogate and clinical outcomes following ischemic postconditioning during primary percutaneous coronary intervention of ST‐Segment elevation myocardial infarction: A meta‐analysis of 15 randomized trials

“…This difference is potentially important because two‐dimensional echocardiography does not have the same accuracy as CMR for ejection fraction determination . In fact, CMR assessments of infarct size and LVEF are the preferred surrogate endpoints for contemporary STEMI trials . No significant differences were noted in rates of reinfarction, stent thrombosis, and target vessel revascularization in our meta‐analysis.…”

Endovascular Therapy for Stroke

“…73 More recently, cardiac magnetic resonance imaging has been used to quantify infarct size, and this tool has been shown to be useful in early clinical trials. 74 An advantage of using infarct volumes in stroke is that it shows the absolute treatment effect of IAT without confounders in the ensuing 89 days that may affect 90-day mRS. Nevertheless, there are still concerns about missing data in patients who die before magnetic resonance image acquisition or those unable to undergo magnetic resonance imaging because of pacemakers or other implants.…”